Targeting B cells in multiple sclerosis.

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• B cell-targeting therapies are increasingly utilized for managing multiple sclerosis (MS).
• Understanding the mechanisms, efficacy, and safety of these treatments is crucial.

Purpose of the Study:

• To review the mechanisms of action, clinical effectiveness, and safety of B cell-targeting treatments for MS.
• To emphasize recently published studies and novel therapeutic approaches.

Main Methods:

• Review of current literature on B cell therapies for MS.
• Analysis of clinical trial data and safety profiles.
• Focus on monoclonal antibodies targeting CD20, CD19, and Bruton's tyrosine kinase (BTK) inhibitors.

Main Results:

• Anti-CD20 monoclonal antibodies demonstrate comparable efficacy in suppressing radiological disease activity and relapse biology in MS.
• Novel strategies include anti-CD19 antibodies and oral BTK inhibitors.
• Key safety concerns include an increased risk of infections and blunted vaccine responses with B cell depletion.

Conclusions:

• Current data support the use of B cell-targeting therapies in MS.
• Further research is needed to establish the advantages of anti-CD19 or BTK inhibitors over anti-CD20 therapies.
• Investigating alternative dosing regimens for anti-CD20 antibodies is warranted to potentially improve safety and immune responses.